文献速递药物相互作用

以患者为中心的药物相互作用评估:整合嵌套临床DDI研究

A Patient-Centered Approach for Drug-Drug Interaction (DDI) Assessment: Integrating Nested Clinical DDI Studies to Verify Translatability of Healthy Volunteer DDI Data, Minimize Stand-Alone Trials, and Enrich Drug Labeling.
PubMed 文献 · Clin Pharmacokinet · 2026-10-21

行业通常假设健康志愿者(HV)的DDI结果可外推至患者,但存在局限。作者回顾FDA近几十年批准发现,嵌套/患者DDI评估被FDA认为足以支持86%新化学实体和92%生物制品的DDI标签。嵌套DDI研究可验证HV到患者的可转化性、减少HV暴露并强化标签。

要点

  • FDA认为嵌套/患者DDI评估足以支持86%新化学实体和92%生物制品的DDI标签。
  • 嵌套DDI研究可验证HV到患者的可转化性并减少HV暴露。
  • 嵌套设计能确认已知相互作用、发现新DDI并弥补PBPK预测缺口。

核心结论

  • 前瞻性整合嵌套DDI研究至开发项目可支持高效风险评估、提升患者安全并改善临床相关性。
  • 监管方与药物开发方应考虑将嵌套设计作为DDI评估的标准组成部分。

研究设计与样本

  • 综述FDA近几十年批准情况,评估嵌套/患者DDI评估对DDI标签的支持作用。

主要发现

  • FDA认为嵌套/患者DDI评估足以支持86%新化学实体和92%生物制品的DDI标签。
  • 嵌套DDI研究可验证HV到患者的可转化性、减少HV暴露、降低操作成本并强化标签。
  • 嵌套DDI研究能确认已知相互作用、发现新DDI并弥补PBPK预测缺口。

关键数值与推荐

  • FDA认为嵌套/患者DDI评估足以支持86%新化学实体和92%生物制品的DDI标签。

临床怎么用

  • 在II或III期临床试验中前瞻性嵌入DDI评估,以验证HV数据向患者的可转化性。
  • 将嵌套DDI设计作为DDI评估的标准组成部分,以支持标签并提升患者安全。

局限性

  • HV的DDI结果可能因疾病相关生理变化而无法外推至患者。
  • 在临床环境中向HV施用研究药物存在伦理与成本问题。
  • PBPK建模在预测多样临床场景的DDI时可能不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The pharmaceutical industry often adopts a stepwise approach, assuming that drug-drug interaction (DDI) results obtained in healthy volunteers (HVs) are translatable to patients. This strategy typically begins with evaluating DDIs in HVs using probe drugs, followed by assessing interactions with potential concomitant medications, often supported by physiologically based pharmacokinetic modeling. Findings from HV studies are subsequently extrapolated to patient populations to inform drug labeling. However, this approach has limitations: (i) DDI results obtained from HV studies may not always be able be to translate to patients due to disease-related physiological changes; (ii) ethical and cost concerns arise when administering investigational drugs to HVs in clinical setting; and (iii) physiologically based pharmacokinetic modeling may be insufficient in predicting DDIs across diverse clinical scenarios. One way to address these challenges is the nested DDI study, where DDI assessments are perceptively embedded within phase II or III clinical trials. [1]. We reviewed US Food and Drugs Administration approvals over recent decades and found that nested/patient-based DDI evaluations were considered sufficient by Food and Drug Administration to support DDI labeling for 86% of new chemical entities and 92% of biologics. This design helps verify HV-to-patient translatability, reduces HV exposure, lowers operational costs, and strengthens labeling. Importantly, nested DDI studies can confirm known interactions, uncover new DDIs, and address gaps in physiologically based pharmacokinetic predictions. In conclusion, prospectively integrating nested DDI studies into development programs supports efficient risk assessment, enhances patient safety, and improves clinical relevance. Regulators and drug developers should consider nested designs as a standard component of DDI evaluation.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Chan CF, Scaringella YS, Huang F, et al. A Patient-Centered Approach for Drug-Drug Interaction (DDI) Assessment: Integrating Nested Clinical DDI Studies to Verify Translatability of Healthy Volunteer DDI Data, Minimize Stand-Alone Trials, and Enrich Drug Labeling. Clin Pharmacokinet. 2026. PMID: 42905252. doi:10.1007/s40262-026-01721-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。